This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Last week, we documented the substantial concentration of dispensing revenues for specialty drugs. See The Top 15 SpecialtyPharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents. Today, we examine how manufacturers’ specialty networks contribute to this concentration.
Last week, we documented the substantial concentration of dispensing revenues for specialty drugs. See The Top 15 SpecialtyPharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents. Today, we examine how manufacturers’ specialty networks contribute to this concentration.
Launched in 2019, NABP’s SpecialtyPharmacy Accreditation was created to accredit pharmacies providing advanced levels of pharmacy services and disease management tools for patients taking medications that require special handling, storage, and dispensing requirements.
Last week, I documented that nearly half of U.S. pharmacies now participate in the 340B Drug Pricing Program. Below, we update our exclusive analysis of the biggest specialtypharmacies within 340B. As you will see below, these specialtypharmacies have dramatically increased their participation in the 340B program.
340B ESP and drug manufacturer restrictions are only part of the reason As we noted in a previous post , for 340B-eligible hospitals dealing with increasingly squeezed bottom lines, an in-house specialtypharmacy offers enormous savings and revenue potential. Hospitals can operate specialtypharmacies alongside their retail pharmacies.
Why a SpecialtyPharmacy? Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. Which is why, according to some online reports, nearly 80% of new drug introductions are now specialty medications. Better Incomes.
Why a SpecialtyPharmacy? Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. Which is why, according to some online reports, nearly 80% of new drug introductions are now specialty medications. Better Incomes.
Why a SpecialtyPharmacy? Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. Which is why, according to some online reports, nearly 80% of new drug introductions are now specialty medications. Better Incomes.
While SaveOnSP is the nominal target of the lawsuit, it claims to expose one of the failings in the US health insurance sector, adding fire to an increasingly heated exchange between pharma manufacturers and pharmacy benefit managers (PBMs), which have blamed each other for high medicine prices in the US.
There are loads of internal hyperlinks to help you navigate the document and customize it to your specific interests and priorities. Many sections and chapters have been expanded and/or reorganized to better cover the latest industry developments.
Customized 340B software should be able to automatically document the journey of every eligible prescription written — from the providers to the retail and specialty contract pharmacies, and from billing to claiming-and-qualifying for 340B reimbursement. For an overview of SpecialtyPharmacy Best Practices, Click Here.
As a specialtypharmacy that works with nurses and medical assistants every day, we hear about your hectic schedules. Courtney Manasco, RPH, is a Pharmacy Manager at Amber SpecialtyPharmacy. Medical Transcriptionist Transcribing medical documents is work you can do from anywhere at hours convenient for you.
According to court documents cited by Reuters, annual sales of Exforge in the US were over $400 million before generic versions reached the market. In 2020, it also paid $345 million to resolve a series of cases brought by the federal government under the Foreign Corrupt Practices Act (FCPA).
In implementing the 2020 final rule, HRSA received questions from stakeholders about the formality of the ADR process and the legal requirements under the FRCP for submitting a petition and accompanying documents, e.g., whether the filings submitted must conform to the FRCP, which added to the complexity and difficulty of the ADR process.
reviews the evolving specialtypharmacy industry and discusses emerging challenges from direct distribution models that bypass wholesale distribution. There are loads of internal hyperlinks to help you navigate the document and customize it to your specific interests and priorities. and Section 6.4.3. A new Section 6.2.2.
The survey attempts to account for the differences in financial reports between pharmacies by asking specific questions about the major points of contention in accounting practices (how do you categorize your rebates? I presume that their fill-at-specialty-pickup-at-retail program counts these rx revenues in the specialtypharmacy division.
The NHC requests more clarity on how CMS will exclude QALY-based metrics and highlight when they have been removed from consideration in MFP justification documentation. Pharmacy benefit managers: transparency, accountability, and impact on patient care. Journal of Managed Care & SpecialtyPharmacy, 27(7), 903-907.
The Citus Health platform goes well beyond a messaging solution, providing us with a complete system of engagement with real-time communications and workflows designed specifically for specialtypharmacy operations.” Pharmacy Services) NKS Assist Ltd. “It
15 The NHC advocates for rigorous, transparent documentation of the medical rationale in such instances to prevent discriminatory practices. Journal of Managed Care and SpecialtyPharmacy, 27(9-a Suppl), doi: 10.18553/jmcp.2021.27.9-a.s17 Section 84.4(e) link] 37 Moczygemba, L., and Johnsrud, M.
Formulary Strategies have several flavors, which generally include: covered or not covered, tiering, quantity limits, prior authorization requirements, step therapy requirements and pharmacy network restrictions (specialtypharmacy only/limited distribution). In the past, the steps also included condoms and OTC spermicides.
I consult with pharmacies to help them understand “DIR fees” – the post-adjudication fees that PBMs contractually force upon pharmacies as a condition of accepting taxpayer-subsidized Medicare Part D business. These fees, as documented by CMS, have increased by 109,000% in the past 10 years.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content